We don’t know the future of this platform for news & knowledge sharing. Just in case, here’s where else you can connect with us: Facebook: facebook.com/GeneEditingDE/ Instagram: instagram.com/geneeditingde/ LinkedIn: linkedin.com/company/christ… #TwitterDown #TwitterShutdown

We're proud to see London McGill, one of our staff scientists, recognized for her presentation at the @AACR McGill presented research on an approach for using CRISPR as a therapy for the treatment of pancreatic cancer. udel.edu/udaily/2024/oc…

It's tomorrow! Join us at Advanced Therapies in Philadelphia to get an insightful glimpse of the field as a whole - from CarT to cell barriers to CRISPR therapeutics! We're presenting and exhibiting, and we hope to see you there! terrapinn.com/congress/advan…

As a nonprofit organization, we rely on philanthropy and donations to continue bringing genomic science to the forefront of medical research while we inspire the next generation of scientists. Interested in supporting us? Visit giving.christianacare.org/gene-editing-i… . Every dollar helps!

Nothing's scary about CRISPR, but there's something spooky about our scientists today! We're enjoying the holiday by dressing up. To all the trick-or-treaters and celebrators of the day: go 'bananas' tonight, but don't go too crazy on the candy - maybe just a 'bite'!

Make sure you don't miss this opportunity to learn about our current research efforts! We hope to see you there!

CorriXR announces the appointment of @JillCastilla to our Board of Directors. She brings visionary leadership as a nationally recognized innovator in finance and banking. “We are thrilled to welcome Jill to our Board and believe she will be an invaluable asset with her vision and…

.@DelawareBio elected two new members to its board of directors: Natalia Rivera-Torres of @GeneEditingDE and Bruce Sachais of the Blood Bank of Delmarva and New York Blood Center Enterprises. delawarebio.org/news/677611/

Our scientific director Eric Kmiec is speaking at Advanced Therapies USA 2024 between November 12-13! Be sure to join his session at America’s leading cell and gene event. Click below now to sign up as his guest! #ADTherapiesUSA i.snoball.it/p/fIW4/sm/1

𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡𝐞𝐫𝐬 𝐑𝐞𝐩𝐨𝐫𝐭 𝐍𝐞𝐰 𝐒𝐭𝐫𝐚𝐭𝐞𝐠𝐲 𝐭𝐨 𝐄𝐧𝐡𝐚𝐧𝐜𝐞 𝐂𝐑𝐈𝐒𝐏𝐑–𝐂𝐚𝐬9-𝐌𝐞𝐝𝐢𝐚𝐭𝐞𝐝 𝐇𝐨𝐦𝐨𝐥𝐨𝐠𝐨𝐮𝐬 𝐑𝐞𝐜𝐨𝐦𝐛𝐢𝐧𝐚𝐭𝐢𝐨𝐧 In a hunt for ways to improve the efficiency of CRISPR–Cas9-mediated homologous recombination, researchers at ETH…

Using CRISPR-Cas9 to knock out CD5, researchers have significantly improved the efficacy of adoptive T-cell therapies for both haematological and solid cancers. We're proud to highlight our fellow researchers in the mid-Atlantic region. crisprmedicinenews.com/news/crispr-en…

In this study, the first example of heritable gene editing in the entire phylum of Tardigrada was researched, evaluated, and deemed a success. This foray into the world of 'water bears' could have major implications for human genome editing in the future. journals.plos.org/plosgenetics/a…

Human cells repair RNA breaks induced by a programmable CRISPR system, paving the way for temporary treatments for genetic diseases. the-scientist.com/a-crispr-tool-…

A team of scientists at Gladstone Institutes has developed a new method that enables them to make precise edits in multiple locations within a cell all at once, opening up the ability to map treatments for complex genetic diseases. gladstone.org/news/new-one-s…

A recent British study at the University of Bristol indicates that the last universal common ancestor (LUCA) possessed an early form of the CRISPR-Cas immune system, dating back approximately 4.2 billion years. crisprmedicinenews.com/news/crispr-or…

Using in vivo AAV-SB-CRISPR, researchers have identified CALHM2 as a key regulator of natural killer cell cytotoxicity, tumor infiltration, and cytokine production. CALHM2-KO CAR-NK cells showed strong antitumor effects in resistant solid tumor models. nature.com/articles/s4158…

Join us for the New Castle County Chamber of Commerce’s 2nd Annual State of the County on Tuesday, July 16, 2024, from 9-2 at University of Delaware’s Clayton Hall Conference Center. Eric Kmiec will be speaking on the institute's progress and future. business.ncccc.com/events/details…

The first therapy using CRISPR genome editing was approved in 2023 to treat blood disorders that affect thousands of people worldwide. But the approach is also a source of hope to many people who have rarer genetic conditions, like the one Uditi Saraf had. nature.com/articles/d4158…

Researchers have developed a new method for precise target selection by using unusual type DEDD transposases. The method, seekRNA, is based on the IS1111 and IS110 insertion sequences and can be reprogrammed to target different sites. crisprmedicinenews.com/news/seekrna-d…

New research shows that many CRISPR screening experiments rely on components, called CRISPR/Cas9 guides, that do not perform equally well in cells from people of all ancestries, which can cause CRISPR screens to miss cancer dependencies. technologynetworks.com/genomics/news/…

It's that time again! We're proud to see Eric Kmiec speak at the Leadership Delaware Speaker Series, highlighting key members of Delaware's innovative political, business, and scientific leaders. Learn more about @LeadershipDel's series model below! leadershipdelaware.org